The Biology of Desire: Seven Pathways That Drive Sexual Function

Why Most Approaches Miss the Mark

Sexual dysfunction follows a narrow clinical script. If a man reports low libido, check testosterone. If he reports erectile dysfunction, prescribe a PDE5 inhibitor. If a woman reports low desire, the conversation often ends with a shrug.

This approach isn't wrong — it's incomplete. PDE5 inhibitors like sildenafil and tadalafil fail to produce a meaningful response in 30–35% of men prescribed them (McMahon et al., BMJ 2006). Testosterone replacement alone frequently fails to restore desire even when serum levels are optimized. And female sexual dysfunction remains largely unaddressed by conventional tools.

The reason is structural. Sexual function — the full arc from desire to arousal to satisfaction — is not a single-pathway phenomenon. It's the output of at least seven interconnected biological systems: a hypothalamic master switch that regulates reproductive hormones, the hormones themselves, a central desire pathway that operates independently of blood flow, a dopamine-driven reward circuit, a vascular response system, a metabolic context that modulates all of the above, and a cellular energy foundation that powers everything.

Think of it like a seven-layer electrical system. When everything is wired and powered correctly, the lights come on seamlessly. When one layer fails, the symptom depends on which layer is affected — and replacing the lightbulb doesn't help when the problem is in the wiring.

Understanding the map changes everything: the diagnosis, the treatment strategy, and the outcome.

Pathway 1: The Master Switch — Kisspeptin and the HPG Axis

Every sex hormone in your body — testosterone, estradiol, progesterone — traces its production back to a single upstream signal: kisspeptin.

Kisspeptin is a neuropeptide produced by specialized neurons in two regions of the hypothalamus: the arcuate nucleus and the anteroventral periventricular nucleus (AVPV). These neurons sit at the top of what's called the hypothalamic-pituitary-gonadal (HPG) axis — the hormonal cascade that governs reproductive function.

The mechanism is elegant. Arcuate kisspeptin neurons are part of the KNDy circuit — named for the three neuropeptides they co-express: kisspeptin, neurokinin B, and dynorphin. These neurons generate rhythmic, oscillatory firing patterns: neurokinin B initiates synchronization, kisspeptin drives the downstream signal, and dynorphin terminates each pulse. This oscillation produces the pulsatile release of GnRH (gonadotropin-releasing hormone) from the hypothalamus, which drives pulsatile LH and FSH secretion from the pituitary, which stimulates testosterone and estradiol production in the gonads.

No kisspeptin signal, no GnRH pulsatility. No pulsatility, no sex hormone production. It is the most upstream lever on the entire reproductive axis.

But the recent science has revealed something more surprising. Research from the Dhillo group at Imperial College London — one of the leading kisspeptin research programs — has demonstrated that kisspeptin doesn't merely regulate hormone production. It directly modulates sexual arousal and brain processing through extrahypothalamic pathways.

In a 2023 randomized trial in men with hypoactive sexual desire disorder (HSDD), kisspeptin administration increased penile tumescence by 56% compared to placebo and enhanced activity in sexual brain network structures on functional imaging (JAMA Network Open, 2023). In a parallel trial in women with HSDD, kisspeptin modulated sexual brain processing on fMRI — participants reported feeling "more sexy" during kisspeptin versus placebo (JAMA Network Open, 2022). A 2025 review in the Journal of Clinical Endocrinology & Metabolism confirmed that kisspeptin signaling extends to the amygdala, bed nucleus of the stria terminalis, and other limbic structures involved in emotional and sexual processing.

So kisspeptin is both the master switch for hormone production and a direct modulator of sexual desire in the brain. It's currently in clinical trials and not yet available for routine clinical use, but its dual nature reframes how we think about the biology of desire.

Pathway 2: The Hormonal Substrate — Testosterone and Estradiol

Kisspeptin sets the stage. The hormones it produces — testosterone and estradiol — are the substrates that every downstream pathway depends on.

Testosterone is the primary driver of sexual desire at the central nervous system level. It acts on androgen receptors concentrated in the medial preoptic area (MPOA) of the hypothalamus — the region most directly implicated in male sexual behavior. The Fifth International Consultation on Sexual Medicine (ICSM 2024) described testosterone as having "a primary role in controlling and coordinating male sexual desire and arousal, acting at multiple levels" (Sexual Medicine Reviews, 2025).

But the relationship between testosterone and the HPG axis is bidirectional. Testosterone feeds back to kisspeptin neurons in the arcuate nucleus, suppressing their activity — this is the negative feedback loop that keeps the system in balance. When testosterone is replaced exogenously (TRT), this feedback suppresses kisspeptin and GnRH pulsatility, effectively shutting down the body's own production. This is why exogenous testosterone impairs fertility — and why kisspeptin, which works with the axis rather than bypassing it, represents a fundamentally different approach.

Estradiol — commonly misunderstood as exclusively a "female hormone" — plays a critical and sex-specific role in both men and women. In women, estradiol exerts positive feedback on AVPV kisspeptin neurons to trigger the preovulatory LH surge, while simultaneously exerting negative feedback on arcuate kisspeptin neurons to regulate tonic GnRH secretion. In men, estradiol is essential for CNS desire signaling, bone health, and cardiovascular function.

One of the most common iatrogenic causes of sexual dysfunction in men is crashed estradiol from overzealous aromatase inhibitor use. Anastrozole — prescribed to reduce estrogen conversion in men on TRT — can suppress estradiol to undetectable levels, and with it, libido, mood, joint comfort, and erectile function. The hormone is not the enemy. The balance is the point.

Pathway 3: The Want Pathway — Melanocortins and MC4R

Hormones set the substrate. But desire — the conscious experience of wanting sexual contact — is driven by a separate neural pathway: the melanocortin system.

Alpha-melanocyte-stimulating hormone (alpha-MSH) and its synthetic analogue bremelanotide (PT-141) act on melanocortin receptors in the hypothalamus, particularly MC4R. Bremelanotide is a nonselective melanocortin receptor agonist with activity across several receptor subtypes (MC1R, MC3R, MC4R, MC5R), but its effects on sexual function are primarily mediated through MC4R. This has been established through knockout studies: mice lacking MC4R show markedly impaired erectile function in males and reduced sexual receptivity in females (PNAS, 2002).

The downstream effect of MC4R activation is dopamine release in motivation and pleasure circuits — specifically in the medial preoptic area and its projections to mesolimbic reward regions. Preclinical research has mapped this pathway in detail: MC4R activation in the MPOA triggers presynaptic dopamine release, creating the neural substrate for sexual motivation (CNS Spectrums, 2022).

This is the critical distinction. The melanocortin pathway is the "want" pathway — and it is mechanistically separate from the vascular "can" pathway that PDE5 inhibitors target. A person with intact blood flow but no desire has a melanocortin problem, not a vascular one. No amount of vasodilation addresses the absence of wanting.

PT-141 was approved by the FDA in 2019 (as Vyleesi) for premenopausal hypoactive sexual desire disorder, based on the Phase 3 RECONNECT trials (Obstetrics & Gynecology, 2019). It remains the only FDA-approved pharmacotherapy that targets central desire rather than peripheral arousal.

Recent research has revealed a direct connection between the melanocortin system and the kisspeptin/HPG axis from Pathway 1. A 2025 eLife study demonstrated that MC4R differentially modulates the two populations of kisspeptin neurons: it excites arcuate kisspeptin neurons while normally inhibiting AVPV kisspeptin neurons — except under elevated estradiol conditions. This gating mechanism allows metabolic signals (energy status, body composition) to regulate reproductive timing through the melanocortin-kisspeptin interface. The desire pathway and the hormone pathway aren't independent systems — they're cross-wired.

Pathway 4: The Reward Circuit — Dopamine and Oxytocin

MC4R activation triggers dopamine release. But dopamine is part of a larger reward architecture that shapes sexual motivation, pleasure, and pair bonding.

Dopamine is the neurotransmitter of wanting — motivational salience, anticipation, the drive toward a rewarding stimulus. The key circuit runs from the ventral tegmental area (VTA) through the nucleus accumbens to the prefrontal cortex. This is the same mesolimbic pathway that drives all motivated behavior: food-seeking, social connection, achievement. Sexual desire recruits this general motivation system, which is why desire doesn't exist in isolation — it's influenced by mood, energy, stress, and competing drives.

Oxytocin, produced in the paraventricular and supraoptic nuclei of the hypothalamus, projects widely to dopaminergic regions: the VTA, striatum, nucleus accumbens, amygdala, hippocampus, and prefrontal cortex (Frontiers in Neuroanatomy, 2020). Its role is bonding, attachment, and the satisfaction that follows consummatory behavior. While dopamine drives toward the experience, oxytocin consolidates after it — reinforcing pair bonds and promoting the desire for future contact with the same partner.

These two systems are not independent. Oxytocin modulates dopamine neuron excitability in the VTA, and oxytocin-dopamine receptor heterocomplexes in the nucleus accumbens create a bidirectional reinforcing loop (Neuroscience & Biobehavioral Reviews, 2024). Desire strengthens bonding; bonding reinforces desire. This convergent architecture explains why sexual satisfaction is relational, not merely mechanical — and why both systems need to be functional for the full experience.

MC4R agonism (PT-141) feeds directly into this dopamine system, which is the mechanistic basis for its clinical effects. Conversely, drugs that increase serotonergic tone — most notably SSRIs — antagonize dopamine activity in these same circuits. This is why SSRI-induced sexual dysfunction is so common and so difficult to manage: the pharmacology directly opposes the reward circuitry that desire depends on.

At the endpoint of this circuit, endogenous opioids (beta-endorphin via mu-opioid receptors) mediate the consummatory pleasure of orgasm, producing a surge that transiently inhibits both dopamine and oxytocin while simultaneously sensitizing both systems for future activation (Sexual Medicine Reviews, 2025). The reward circuit isn't a single switch — it's a sequence of neurochemical events, each of which can be the point of disruption.

Pathway 5: The Vascular Response — Nitric Oxide and PDE5

Central desire must eventually translate into physical arousal — which requires the vascular machinery to respond.

The classical pathway: sexual stimulation activates parasympathetic nerves in the genital vasculature, triggering the release of nitric oxide (NO) from endothelial cells and nitrergic neurons. NO activates guanylate cyclase in smooth muscle cells, which produces cyclic GMP (cGMP). cGMP accumulation causes smooth muscle relaxation, vasodilation, and increased blood flow — the physical basis of erection in men and clitoral engorgement in women.

PDE5 (phosphodiesterase type 5) is the enzyme that degrades cGMP, terminating the vascular response. PDE5 inhibitors — sildenafil (Viagra), tadalafil (Cialis), vardenafil, avanafil — competitively block PDE5, preventing cGMP breakdown and prolonging vasodilation.

This is the most widely prescribed class of sexual dysfunction medications in the world. It's also the most frequently misapplied — because it has a critical prerequisite that often gets overlooked.

Endothelial health is the other critical variable. Damaged endothelium — from diabetes, hypertension, smoking, metabolic syndrome — produces less NO regardless of arousal signal strength. This is why erectile dysfunction and cardiovascular disease share the same root cause (endothelial dysfunction) and why ED often presents as an early warning signal for cardiovascular events. Vascular repair compounds (BPC-157, thymosin beta-4) that promote angiogenesis, endothelial NO synthase activation, and microvascular integrity address this layer — not by enhancing PDE5 inhibition, but by restoring the tissue that PDE5 inhibitors depend on.

The vascular pathway is real, important, and well-served by existing pharmacology. It's also only one layer of a seven-layer system.

Pathway 6: The Metabolic Intersection — GLP-1/GIP and Sexual Function

All of the pathways above exist within a metabolic context — and modern metabolic interventions have unexpected effects on sexual function.

GLP-1 receptor agonists (semaglutide, tirzepatide) are the most significant pharmacological development in metabolic medicine in decades. GLP-1 receptors are broadly expressed in hypothalamic nuclei, and emerging evidence suggests that GLP-1 agonist effects on sexual behavior are mediated primarily through mesolimbic reward pathways — the laterodorsal tegmental area and posterior VTA — rather than through classical hypothalamic sexual centers.

This creates a paradox. GLP-1 agonists can blunt libido — a proposed mechanism involves serotonergic modulation via 5-HT2C receptor pathways, analogous to the well-documented sexual side effects of SSRIs (Gelfand et al., Obesity Pillars, 2025). This mechanism is biologically plausible but not yet experimentally confirmed. A TriNetX database study of semaglutide users found higher rates of newly diagnosed erectile dysfunction (1.47% vs. 0.32%) and testosterone deficiency (1.53% vs. 0.80%) compared to matched controls (International Journal of Impotence Research, 2025).

At the same time, GLP-1 agonists improve hormonal profiles in men with obesity. A 2025 meta-analysis of seven studies (n=680) found that GLP-1 receptor agonists significantly increased total testosterone, LH, and FSH levels in men with overweight and obesity (Andrology, 2025). The mechanism is indirect: reduced adiposity decreases aromatase activity and inflammatory signaling, improving HPG axis function.

The net effect depends on where you start. In metabolically unhealthy, obese folks, the hormonal improvement from weight loss may outweigh any direct libido-blunting effect. In leaner folks, the serotonergic suppression may dominate.

This is a concrete example of why the systems view matters. A recently completed Phase 2 trial (BMT-801, NCT06565611) tested the combination of bremelanotide (MC4R agonist) with tirzepatide (GLP-1/GIP agonist) for obesity and met its primary endpoint with a 4.4% weight reduction. The rationale was dual: MC4R activation may enhance satiety signaling synergistically with GLP-1/GIP agonism, and it directly counteracts the libido-blunting mechanism through the desire pathway. One intervention addresses the metabolic problem; a second protects the sexual function pathway that the first disrupts. That's systems thinking applied to pharmacology.

Pathway 7: The Foundation — Cellular Energy and Circadian Rhythm

Every pathway described above — from kisspeptin pulsatility to NO synthesis — requires cellular energy to function. The bottom layer of the system is mitochondrial capacity and circadian regulation.

Steroidogenesis is ATP-intensive. The conversion of cholesterol to pregnenolone — the rate-limiting step in sex hormone production — occurs inside the mitochondria of Leydig cells in the testes and theca cells in the ovaries. MOTS-c, a mitochondrial-derived peptide that activates AMPK signaling, directly supports the metabolic machinery that powers this process. Neurotransmitter synthesis (dopamine, serotonin, norepinephrine) requires mitochondrial substrates. Endothelial NO production requires NADPH, generated through mitochondrial metabolic pathways.

Circadian biology is equally foundational. The HPG axis is circadian-gated: testosterone follows a diurnal rhythm, peaking in the early morning and reaching its nadir in the evening. This rhythm is driven by pulsatile GnRH secretion, which is itself influenced by the suprachiasmatic nucleus — the body's master clock. Deep sleep is a physiologic prerequisite for morning testosterone peaks; sleep disruption directly impairs HPG axis output.

Compounds that support mitochondrial function — SS-31 for cardiolipin stabilization, NAD+ for electron transport and sirtuin activation, CoQ10 for electron shuttling — don't target sexual function directly. They support the cellular infrastructure that every sexual function pathway depends on. When this layer is compromised by age, sleep disruption, metabolic disease, or chronic stress, interventions at higher layers operate at reduced capacity.

Why Single-Pathway Approaches Fail

With the full map in view, the clinical failures become legible.

The "Cialis didn't work" patient. A man with normal testosterone, normal vascular health, and no response to a PDE5 inhibitor. The reflex is to increase the dose or switch agents. But the problem is upstream: if desire-phase signaling (melanocortin pathway) is insufficient, there's no arousal signal to amplify. The vascular machinery is waiting for an input that never arrives. The correct intervention targets MC4R, not PDE5.

The "TRT didn't fix my libido" patient. Testosterone has been optimized — levels are in the upper quartile, free testosterone is adequate. But desire remains absent. Two common explanations emerge from the map. First: estradiol has been suppressed by concurrent aromatase inhibitor use, removing a critical component of CNS desire signaling. Estradiol is not a side effect of testosterone therapy — it's a necessary downstream product. Second: the melanocortin and dopamine pathways were never assessed. Optimizing the hormonal substrate doesn't automatically activate the desire and reward circuits that depend on it.

The "I lost my libido on Ozempic" patient. Excellent metabolic improvement — weight loss, improved insulin sensitivity, normalized blood glucose — but a marked decline in sexual desire. The metabolic intervention is working as intended, but its interaction with serotonergic and dopaminergic circuits in the reward pathway produces a predictable and addressable side effect. This is not a reason to stop the metabolic therapy. It's a reason to assess and support the desire pathway concurrently.

Each of these scenarios maps directly to the seven-pathway framework. The diagnosis changes when you see the full system.

Thinking in Systems: The Integrated Approach

Sexual function is not a single-pathway problem. The layered architecture suggests a layered response.

Layer	Target Pathway	Mechanism	Clinical Status
Upstream regulation	Kisspeptin / HPG axis	GnRH pulsatility → endogenous hormone production	Clinical trials (not yet available)
Hormonal substrate	Testosterone / Estradiol	Androgen and estrogen receptor activation in CNS and periphery	Available (TRT, hormone optimization)
Central desire	MC4R / Melanocortin	Hypothalamic dopamine release → desire and motivation	FDA-approved (PT-141 / bremelanotide)
Reward and bonding	Dopamine / Oxytocin	Mesolimbic motivation, pair bonding, satisfaction	Supportive (substrate optimization, lifestyle)
Vascular response	NO / cGMP / PDE5	Endothelial vasodilation → physical arousal	Available (PDE5 inhibitors, vascular repair)
Metabolic context	GLP-1 / GIP interaction	Metabolic-reproductive crosstalk	Available (with monitoring for sexual side effects)
Cellular foundation	Mitochondria / Circadian	ATP for steroidogenesis, neurotransmission, NO synthesis	Available (mitochondrial support, sleep optimization)

The principle is straightforward: interventions compound when they target different nodes. Optimizing testosterone (Layer 2) while leaving the melanocortin pathway unaddressed (Layer 3) produces a partial response. Adding PDE5 inhibition (Layer 5) to someone with adequate vascular function but impaired desire adds nothing. But addressing hormonal substrate, central desire, vascular health, and cellular energy simultaneously — each at the appropriate layer — produces effects that are greater than the sum of individual interventions.

This is not polypharmacy for its own sake. It's targeted intervention at identified points of dysfunction, guided by the biology of the system rather than the convenience of a single prescription.

Where This Is Heading

The science of sexual function is moving rapidly from single-target to systems-level interventions.

Kisspeptin is the most promising upstream target in the pipeline. A 2025 study demonstrated that intranasal kisspeptin administration rapidly stimulates gonadotropin release in healthy volunteers and in women with hypothalamic amenorrhea (EBioMedicine, 2025) — a potential breakthrough in delivery that could make kisspeptin clinically practical. Ongoing trials at Massachusetts General Hospital (NCT05896293) are expanding the evidence base for kisspeptin in hypogonadotropic hypogonadism. A safety study of 95 participants found no adverse effects on anxiety, cortisol, blood pressure, or heart rate (JCEM, 2025), reinforcing the favorable profile of a compound that works with the body's own hormonal axis rather than replacing it.

The BMT-801 trial (NCT06565611) — the first to combine an MC4R agonist with a GLP-1/GIP agonist — has completed Phase 2 with positive results. This is the first empirical test of the metabolic-sexual synergy hypothesis: that melanocortin activation can both enhance satiety and protect sexual function during metabolic pharmacotherapy.

Bremelanotide combined with PDE5 inhibitors — addressing both central desire and peripheral vasodilation in a single regimen — entered Phase 2 clinical evaluation in 2024 and is progressing toward Phase 2/3. This combination specifically targets the 30–35% of folks for whom PDE5 inhibitors alone are insufficient, on the mechanistic basis that the missing ingredient is central arousal, not additional vasodilation.

The trajectory is clear: from treating single symptoms to modulating interconnected systems. From asking "which drug?" to asking "which pathways?" The biology has always been complex. The clinical tools are finally catching up.

Sexual function is not a single-pathway problem, and it doesn't require a single-pathway solution. The biology is layered, interconnected, and responsive to intervention at multiple nodes. The question is whether the clinical approach matches the biological reality.